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Abstract: The discovery of induced pluripotent stem cells (iPSC) 12 years ago has fostered the 
development of innovative patient-derived in vitro models for better understanding of disease 
mechanisms. This is particularly relevant to neurodegenerative diseases, where availability of live 
human brain tissue for research is limited and post-mortem interval changes influence readouts from 
autopsy-derived human tissue. Hundreds of iPSC lines have now been prepared and banked, thanks 
to several large scale initiatives and cell banks. Patient- or engineered iPSC-derived neural models 
are now being used to recapitulate cellular and molecular aspects of a variety of neurodegenerative 
diseases, including early and pre-clinical disease stages. The broad relevance of these models derives 
from the availability of a variety of differentiation protocols to generate disease-specific cell types 
and the manipulation to either introduce or correct disease-relevant genetic modifications. Moreover, 
the use of chemical and physical three-dimensional (3D) matrices improves control over the 
extracellular environment and cellular organization of the models. These iPSC-derived neural models 
can be utilised to identify target proteins and, importantly, provide high-throughput screening for 
drug discovery. Choosing Alzheimer‘s disease (AD) as an example, this review describes 3D 
iPSC-derived neural models and their advantages and limitations. There is now a requirement to 
fully characterise and validate these 3D iPSC-derived neural models as a viable research tool that is 
capable of complementing animal models of neurodegeneration and live human brain tissue. With 
further optimization of differentiation, maturation and aging protocols, as well as the 3D cellular 
organisation and extracellular matrix to recapitulate more closely, the molecular  
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extracellular-environment of the human brain, 3D iPSC-derived models have the potential to deliver 
new knowledge, enable discovery of novel disease mechanisms and identify new therapeutic targets 
for neurodegenerative diseases. 
Keywords: induced pluripotent stem cells; neural stem cells; 3D; culture model; microenvironment; 
matrix; neural differentiation; neurodegenerative diseases; Alzheimer 
 
Abbreviations: AD: Alzheimer‘s disease; ALS: Amyotrophic Lateral Sclerosis; AMPA: 
Aminomethylphosphonic Acid; APP: Amyloid precursor Protein; ECM: Extracellular matrix; EMT: 
epithelial-mesenchymal transition; EPSC: excitatory postsynaptic potential; ESCs: embryonic stem 
cells; fAD: familial Alzheimer Disease; FTD: Frontotemporal dementia; GABA: Gamma-
Aminobutyric Acid; GSK: glycogen synthase kinase; HGPS: Hutchinson-Gilford progeria syndrome; 
iN: induced neurons; iPSC: induced pluripotent stem cells; LIF3: Leukaemia Inhibitory Factor 3; 
MEAs: microelectrode arrays; NMDA: N-methyl-D-aspartate; NSCs: neural stem cells; PS1: 
presenilin1; RAN: Repeat-associated non-ATG; TGFβ: transcription growth factor beta; UPR: 
unfolded protein response; 3D: three-dimensional; 2D: two-dimensional 
1. Introduction 
In 2006 Yamanaka and Takahashi published their seminal work on induced pluripotent stem 
cells (iPSC) technology, by forcing expression of key transcription factors, Klf4, Sox2, c-myc and 
Oct3/4 to reprograme somatic cells back to an undifferentiated state capable of unlimited proliferation. 
This provided laboratories with a tool for continuous supply of human pluripotent cells [1]. Since then, 
the use of iPSCs in research has expanded exponentially. Over a decade later, researchers can now 
use patient-specific iPSCs to create many neural cell types, including those that are involved in 
neurodegeneration. It is now possible to study patient-derived mature neurons and glia in  
two-dimensional (2D) monolayer culture and, more recently, in three-dimensional (3D) culture 
thereby investigating disease pathogenesis in a more translational context. There is currently 
intensive research into the feasibility of 3D neural cultures for disease modelling and drug screening; 
however, recapitulating maturation and aging in a model of age-related disease is still a challenge. 
Can 3D cultures deliver what they promise or will they just be another research tool to 
complement traditional disease models? 
2. iPSCs as a tool for in vitro research relevant to neurological diseases 
One major advantage of iPSCs is that they negate the ethical concerns regarding the use of 
embryonic or foetally-derived cells, and they can now be produced using virus-free methods [2–5]. 
The use of adult somatic cells for iPSC production is widely ethically approved and provides 
autologous non-immunogenic cells that can be used for cell transplant and personalised medicine. In 
particular, these cells can generate autologous dopaminergic neurons for the treatment of Parkinson‘s 
disease to replace the use of implanting neural progenitor/stem cells from foetal/embryonic sources 
which can cause tumour formation and illicit a deleterious immune response [6,7]. One other 
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advantage of iPSCs is their isogenicity to a patient, recapitulating the exact genetic information 
leading to the disease. For example, iPSC-derived from familial AD (fAD) patients harbouring 
mutations in amyloid precursor protein (APP), presenilin-1 (PS1) or -2 genes can be used to 
recapitulate in vitro the cellular events that induce early stages of disease pathology. This enables 
scientists to unravel the underlying mechanism(s) underpinning the disease [8–10]; it also overcomes 
the issue of using model species that do not develop these human diseases de novo. 
IPSCs can now be easily inducted along the neural lineage using dual smad inhibition, Noggin 
and SB431542 [11,12]. This method has also been refined by modifying the original protocol and 
relies on three small molecules to inhibit the following signalling pathways: glycogen synthase 
kinase (GSK)-3 beta with CHIR99021, transcription growth factor beta (TGFβ) with SB431542, and 
Notch with compound E, along with human Leukaemia Inhibitory Factor 3 (LIF3) [13]. This new 
small molecule-based neural differentiation protocol increased neural differentiation kinetics and 
allowed the derivation of truly multipotent neural stem cells (NSCs) that respond to regional 
patterning cues specifying forebrain, midbrain, and hindbrain neural and glial subtypes (see Table 1). 
In several neurodegenerative diseases, age is a major risk factor. This suggests a long incubation 
time for the pathology to develop, taking years for clinical symptoms to appear. This period has been 
defined as the biochemical and cellular phases occurring before the clinical phase, in a recent review 
on Alzheimer‘s disease (AD) [14]. The biochemical phase is described as the phase of abnormal 
aggregation of Abeta and processing of APP, tau aggregation and hyperphosphorylation, up to the 
generation of amyloid plaques and neuronal tangles. The cellular phase is described as a phase with 
defective clearance mechanisms of Abeta and tau, happening both within the cell, occurring possibly 
as a result of impaired autophagic and proteosomal clearance, and outside the neurons within the 
neurovascular unit. Both these phases are essential in the appearance of clinical symptoms and are 
the focus of research into the causes and mechanisms of the disease. Using a model that recapitulates 
these phases in human cells is a promising avenue. Cell culture models from patient iPSCs 
recapitulate this long incubation period corresponding to the biochemical and cellular phases, with 
disease-causing mutation present during development, maturation and aging of the cells. In these 
models, observations are possible at different time points to study the development of the 
pathological features. The use of isogenic iPSCs allows the observation of early disease phases in 
physiologically relevant conditions, without the need to transduce or overexpress specific 
components of the disease pathology. 
Neurodegenerative disease pathophysiology involves degeneration of neurons, with possible 
involvement of astrocytes, endothelial cells, microglia and oligodendrocytes. The use of iPSC 
models allows for the generation of isogenic cell types and design of culture with these cells in 
isolation or combination to study their individual role in the disease pathophysiology. This might 
allow the identification of specific cells to target in the design of new therapeutic strategies. Indeed, 
key roles of glial cells in schizophrenia [15], Amyotrophic Lateral Sclerosis (ALS) [16–18], 
Frontotemporal dementia (FTD) [19] and AD [20] have for example been shown using iPSCs. 
In the field of toxicology and drug testing, high-throughput experiments are usually necessary to 
screen large numbers of candidates. Using an iPSC-derived model allows the generation of an almost 
unlimited source of functional lineage-specific cells and is thus perfectly compatible with the  
high-throughput experimental design required. Moreover, toxicity testing on diseased and healthy 
cells can be done in parallel on isogenic differentiated cell types and 3D reconstructed tissue in vitro, 
an area in which 3D cultures could promise cost effective toxicity testing. For example,  
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iPSCs-derived neurons have already been used in high-throughput screening and resulted in the 
identification of several compounds with some activity to reverse Fragile X syndrome [21]. 
One of the main issues with the use of iPSC-derived models is the variability within cell lines 
and derivation techniques. To overcome this to some extent, established iPSC lines (following 
standard protocols and characterization) are now expanded and banked in open access or commercial 
cell banks (Table 2). This provides uniformity in cells used across laboratories and will hopefully 
lead to reproducible results across research groups. 
Overall, iPSC-derived models provide a promising tool for neurodegenerative disease research, 
and due to their increased accessibility to the large scientific community through cell banks, they are 
already leading to new discoveries in this area. 
Table 1. Differentiation methods of human iPSC-derived neural progenitors. 
Cell types Protocols Results References 
Astrocytes cAMP (1 µM) S100ß+ (6 weeks),  
GFAP+ (12 weeks) 
[22] 
BDNF & GDNF (20 ng/ml) GFAP+ (19% at 8 weeks) [104] 
CNTF, FBS (10%)  [110] 
BDNF & NT3 (20 ng/ml) GFAP+ [102] 
BDNF (10 ng/ml), SHH (200 
ng/ml), GDNF (10 ng/ml), IGF 
(10 ng/ml), CNTF (10 ng/ml), 
FBS (1%), FGF1/2 (50 ng/ml) 
GLT1+ GLAST+ [111] 
CNTF (5 ng/ml), BMP2 (10 
ng/ml), heregulin (10 ng/ml) 
∼70% GFAP+ (5 weeks) [112] 
Oligodendrocytes T3, PDGF-AA, IGF1, NT3 O4+ (16 weeks) [22] 
BDNF& GDNF (20 ng/ml) OLIG2+ , CNPase+, 
NogoA+ , BMP+ (42%) 
and myelinating-like 
processes (8 weeks) 
[104] 
PDGF-AA (5 ng/ml), IGF-1  
(5 ng/ml), NT3 (5 ng/ml), BDNF 
(10 ng/ml) 
20–40% CD140a+, 5–10% 
O4+ (21 weeks) 
[113] 
all-trans RA (100 nM) followed 
by SHH agonist SAG (1 μM) 
44–70% O4+ (11 weeks) [114] 
Continued on next page 
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Cell types Protocols Results References 
Neurons Retinoic acid(100 nM), SHH  
(100 ng/ml), cAMP, (1 µM) 
cultured on laminin substrate 
TUJ1+, HOXC8+  
(6 weeks) 
[22] 
BDNF & GDNF (20 ng/ml) TUJ1+, VGlut+, SYN+  
(8 weeks) 
[104] 
Growth factor removal, 
immunopanning using NCAM. 
MAP2+ (90%), Voltage 
gated Na+ & K+ currents 
and TTX sensitivity  
(8 weeks) 
[115] 
 
FGF8, PMA and AA on matrigel, 
followed by BDNF, GDNF & 
TGF-ß3 (10 ng/ml), AA (200 
µM), & cAMP (500 µM). 
TUJ1+, evoked APs & 
TTX sensitivity (4 weeks) 
[92] 
 
FBS (10%) on a gelatin substrate TUJ1+, SYN+ (2 weeks) [91] 
Cortical neurons Growth factor removal on laminin 
substrate 
MAP2+, PSD95+. SYN+, 
VGlut1+, Tbr1+, Ctip2+ 
Evoked APs 
[12] 
 
BDNF & GDNF (10 ng/ml) on 
laminin substrate 
MAP2+, SYN+, Tbr1+, 
Brn2+, Ctip2+ (4 weeks)  
[110] 
BDNF & NT3 (20 ng/ml) NeuN+, MAP2+ [102] 
Motor neurons Laminin substrate, BDNF, GDNF, 
IGF1 (10 ng/ml) 
ChAT+, BTX+, HB9+ 
(10–23%), ISL1/2+, 
spontaneous post synaptic 
currents detected (>8 
weeks) 
[116] 
Purmorphamine(1 µM) & 
CHIR99021(3 µM) followed by 
BDNF(10 ng/ml) 
 ISL1 & HB9(d42), evoked 
Aps (d30) 
[117] 
Mid-brain 
neurons 
FGF8a, SHH, AA TH+, En-1+, FOX2A+, 
DAT+. VMAT2+, 
AADC+ 
[118] 
FGF8a, SHH, RA FOX2A+, TH+, TUJ1+ [119] 
FGF8, PMA and AA on matrigel, 
followed by BDNF, GDNF & 
TGF-ß3 (10 ng/ml), AA (200 
µM), & cAMP (500 µM). 
TH+, FOXA2+ (50%) [92] 
Continued on next page 
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Cell types Protocols Results References 
Dopaminergic 
neurons 
Laminin substrate, matrigel, 
BDNF & GDNF added at day 70 
TH+, En-1+, FOX2A+, 
DAT+. VMAT2+, 
AADC+, spontaneous APs, 
EPSC, voltage gated Na+& 
K+ currents and NMDA 
and GABA gated currents 
[118] 
BDNF& GDNF (20 ng/ml) TH+ (8 weeks) [104] 
Glutamatergic 
neurons 
FGF2 & Cyclopamine (400 ng/ml) 
followed by BDNF (10 ng/ml) 
Glutamine+, VGluT1+ (6 
weeks) 
[120] 
Cyclopamine(1 µM) followed by 
BDNF(10 ng/ml) 
VGlut1+ TBR1+ (d35) & 
Glutamine+ (d55) 
[117] 
Ngn2 induction followed by 
Laminin (1 μg/ml) BDNF (10 
ng/ml) & NT3 (10 ng/ml) 
NeuN+, MAP2+ , TUJ1+, 
spontaneous post synaptic 
currents blocked by CNQX 
(d28) 
[121] 
GABAergic 
neurons 
FGF2 followed by BDNF  
(10 ng/ml) 
GABA+ (6 weeks) [122] 
FGF8, PMA and AA on Matrigel, 
followed by BDNF, GDNF & 
TGF-ß3 (10 ng/ml), AA(200 µM), 
& cAMP (500 µM) 
GABA+(45%) [92] 
Cholinergic 
neurons 
FGF8, PMA and AA on Matrigel, 
followed by BDNF, GDNF & 
TGF-ß3 (10 ng/ml), AA(200 µM), 
& cAMP (500 µM) 
ChAT+ (3%) [92] 
Serotonergic 
neurons 
SHH & FGF4 followed by BDNF, 
GDNF, IGF1(all 10 ng/ml) & 
TGFβ3 (1 ng/ml) 
Serotonin+, TPH2+, 
serotonin release in 
response to tramadol  
(6 weeks) 
[123] 
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Table 2. Some of the major iPSC banks with notably cells from neurological patients. 
Cell bank/ Company Location Disease types No. of lines 
developed 
StemBANCC EU Neurological diseases 
Diabetes 
Drug Testing 
500 
EBiSC- IMI EU Age-related macular degeneration 
Frontotemporal dementia 
Bardet-Biedl syndrome 
Amyotrophic lateral sclerosis 
Parkinson‘s disease 
Diabetes 
367 
Cellular Dynamics 
International - Fujifilm 
Company 
USA  Viral Hepatitis and non-alcoholic 
Steatohepatitis 
Autism Spectrum disorders  
Cardiovascular diseases  
Idiopathic Pulmonary disease 
Alzheimer‘s disease  
Neurodevelopmental disabilities 
Blinding Eye disease 
1,424 
HipSci (Sanger 
institute) 
UK Bardet-Biedl syndrome 
Monogenic diabetes 
Usher syndrome 
Congenital eye defects 
700 control 
lines and 100 
disease lines 
  
CIRM – Coriell Institute 
for Medical Research 
(California Stem Cell 
Agency) 
USA Cardiomyopathies  
Blinding Eye Diseases 
Lung Diseases 
Neurodevelopmental Disorders 
Alzheimer's Disease 
Liver Diseases 
1,429 
3. Methods of iPSC differentiation and maturation for modelling aspects of 
neurodegeneration 
A variety of cells can now be generated from iPSC-derived neural epithelial cells using timed 
exposure to different growth factors and small molecules, to encourage the differentiation of neural 
progenitors along specific lineages (Table 1). For models of neurodegeneration, different protocols 
are required to obtain the specific neural cell types involved in different diseases e.g. dopaminergic 
neurons for Parkinson models, Schwann cells for multiple sclerosis whereas cholinergic cortical 
neurons are of interest for AD models (specific protocols for different phenotypes are listed in Table 1). 
The iPSC-derived cells can be patterned in the same manner as neural stem cells, however there 
is often large variability and reduced efficiency in producing neurons from iPSCs compared to 
embryonic stem cells (ESCs) [22] along with an apparent delay in maturation. Mature 
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electrophysiological responses in ESC-derived neurons occur after 3 weeks of differentiation [23,24], 
but appears to be delayed to around 8 weeks in iPSCs-derived neurons [22,25], although both 
neuronal populations show the same functional properties [26]. It has been suggested that using late 
rather than early passage iPSCs, increases the capacity of neuronal differentiation and maturation in 
these cells [27]. 
Evidence of functionality is one of the most important feature to be observed in any 3D iPSC 
model through neurotransmitter release and firing of action potentials. To date there is a lack of 
electrophysiological characterisation of 3D cultures, particularly from patient-derived neurons. Choi 
et al. conducted electrophysiology in their premature and mature control ReN cells to show they 
contained voltage-gated sodium and potassium currents, the former being blocked with TTX [28]. 
However, more patch clamp, biochemical and immunohistochemical studies are needed in this model 
to determine the ability of differentiated neurons to elicit sustained action potentials, form functional 
synapses expressing key structural proteins and receptors such as N-methyl-D-aspartate (NMDA) 
receptors, required for induction of long-term potentiation and memory and other AD-relevant 
proteins (e.g. the sodium calcium exchanger 3) [29]. 
Producing different neuronal subtypes from iPSCs is now becoming routine (Table 1) and there 
are efforts to standardise protocols between laboratories. However, neuronal maturation to produce 
terminally differentiated and functional neurons to study disease mechanisms is still a challenge. In 
the developing brain there is sequential expression of gamma-aminobutyric acid (GABA) a, NMDA 
and aminomethylphosphonic acid (AMPA) receptors [30] along with receptor subunit switching to 
initiate synaptogenesis and maturation. Immature cells of the mammalian dentate gyrus are highly 
excitable and exhibit reduced GABAergic inhibition; this allows initial communication, enabling 
formation of synapses, but the excitability then decreases. One may therefore predict nascent 
neuronal networks, formed in vitro, to exhibit high levels of excitatory postsynaptic potential (EPSC) 
and action potentials that reduce in frequency over time. So far only a gradual increase in excitability 
has been recorded using patch clamp or multielectrode array (MEA) methods [22,31]. Investigations 
into levels of GABAergic interneurons and receptor subunit expression in 3D neural cultures may 
indicate how representative these models are of the in vivo situation. 
Sensory deprivation during olfactory bulb development is known to reduce survival and density 
of excitatory neurons [32,33]. The environment in which neuronal cultures are maintained does not 
recapitulate this variation of stimulation: incubators have constant oxygen tensions and cells are in 
highly buffered media void of exogenous factors, except for those that are provided (Table 1). To 
increase external stimuli, neurons can be cultured under electronic stimulus using conductive 
scaffolds and MEAs, Pires et al. found these conditions increased neuronal differentiation and 
neurite outgrowth [34]. In addition, a new culture media ‗BrainPhys‘ has exhibited improved 
excitability in vitro, by supporting neuronal survival and activity, and, with long-term exposure, by 
enhancing neuronal synaptic function [35]. 
As many neurodegenerative diseases are associated with aging, and iPSC-derived neurons 
usually age only for a few weeks, their utility as a model for age-related neurodegenerative diseases 
has been questioned. Some studies have attempted to partly address these issues: for example, by 
using cells from patients with early onset neurodegenerative disease patients as in fAD or by forcing 
the iPSC-derived neurons to age prematurely. For the latter, there has been interest in expressing 
progerin, a protein involved in severe premature aging. This protein is implicated in Hutchinson-
Gilford progeria syndrome (HGPS), a rare genetic disorder in which a truncated form of lamin A, 
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progerin, is expressed, leading to defects in DNA repair mechanisms, premature senescence and a 
very shortened lifespan [36]. IPSCs-derived neurons expressing progerin induce multiple  
aging-related markers and characteristics such as a decrease of dendrite branching and an increase of 
neuronal aging process transcripts) [37]. Moreover, progerin-expressing neural stem cells have a 
reduced proliferation rate similar to aged neural stem cells as well as some accumulation of damaged 
proteins [38]. 
Another route to obtain ‗aged‘ neurons is through direct conversion of fibroblast to neurons by 
reprogramming with a set of transcription factors without reversion to pluripotent state [39–42]. 
These induced neurons (iN) provide a new approach for patient-specific disease modelling as they 
preserve donor age-dependent transcriptomic signatures which are erased in iPSCs as they are 
reverted to a undifferentiated state [43]. A recent study showed generation of induced dopaminergic 
neurons exhibiting functional dopaminergic neurotransmission by direct differentiation method from 
human fibroblasts bypassing the lengthy in vitro differentiation time. These cells relieve locomotor 
symptoms when transplanted in Parkinson‘s disease animal model [44]. Although the iN technology 
has been available for over 5 years, it is not widely used, possibly due to the low efficiency along 
with limited proliferative capacity, restricted lineage and difficulties in scaling up the process. 
With increasing interest in producing neural subtypes from iPSCs, many labs are developing 
methods to produce specific cell types (summarized in Table 1) as well as new methods for 
maturation and aging, but there is a need for homogenisation and validation of protocols if these 
neural models are to be compared and utilised for drug discovery. 
4. 3D iPSC neural models 
4.1. 2D versus 3D cell cultures 
2D iPSC cultures are suited to individual cell populations or co-cultures, allowing easy access to 
cells and enabling electrophysiological recordings to study synaptic function [45–47], but 2D 
cultures do not recapitulate in vivo environment as well as 3D cultures. Monolayer cultures have less 
paracrine cell communication and cell-cell contacts. These cell communications provided by 
oligodendrocytes and astrocytes are crucial for neuronal behaviour and plasticity. For example, 
Burkhardt et al. observed electrical activity in iPSC-derived neurons at 2 weeks when cultured on 
astrocytes compared to 3 months when cultured without [8,48]. Pre et al. observed improved resting 
membrane potentials and a greater number of cells producing action potentials in the iPSCs-derived 
neurons co-cultured with glia. Moreover, 3D cultures show several advantages over 2D including 
increased viability, neurite outgrowth and synaptic density [49–52]. 
4.2. Current 3D culture models 
Several different types of 3D neural models now exist, each with their own distinct properties; 
one unifying advantage of 3D culture design is the structural components in their extracellular milieu. 
By providing the 3D space for cells to secrete extracellular matrix (ECM) proteins that can sequester 
secreted proteins, as well as retain growth factors and signalling molecules that would otherwise be 
washed away in 2D cultures, 3D cultures will more accurately model the in vivo environment. For 
instance, chemokines secreted by microglia were found to increased NSC polarisation and migration 
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in 3D graphene foams but not on 2D graphene films [53], demonstrating that neural cells grown in 
3D culture are more responsive to chemokine cues, possibly due to greater retention of these 
compounds in the 3D environment.  
Cerebral organoids developed from iPSCs are ideally suited to study early brain developmental 
processes, as they spontaneously recapitulate a multi-layered structure, similar to the mammalian 
cortex [54]. Cerebral organoids have been used to study different diseases such as the microcephaly 
caused by the ZIKA virus. Indeed, they have been used to decipher the virus mode of action [55–58], 
showing that the virus targets neural progenitors to kill them. Cerebral organoids were also used to 
screen libraries to find anti-ZIKA virus compounds targeting neural progenitor cell death as well as 
viral replication [59–61]. Cerebral organoids have thus been essential in these steps forward to 
clinical trial for ZIKA infection treatment. 
Organoids can grow much larger than 3D cultures but their size is limited to around 400µm in 
diameter by the nutrient availability and waste removal in the organoid core, which can become 
necrotic. They also exhibit high variability between experiments and are generally low throughput. 
They are limited in differentiation and maturation as their maturation is usually equivalent to human 
mid to end of gestation brain maturation stage. 
By contrast, human organotypic slices from adult brain tissue are suited to study disease/normal 
state in adults, with most examples coming from epilepsy or brain tumour tissue [62–65]. Only a few 
studies have been carried out with ―healthy‖ brain tissue [66,67], including one using Abeta 
oligomers [68]. These ex vivo cultures are still the closest we can achieve to a human model, the 
innate structure is maintained and they include microglia, blood vessels and parts of the blood-brain 
interface. However, availability of tissue from neurodegenerative patients is very low, healthy brain 
tissue from patients is rare and mostly comes from tumour de-bulking surgeries or cortex removed to 
access deep brain regions. Long-term culture remains a challenge and genetic manipulations to test 
disease hypotheses are not yet possible. 
An alternative is ‗Hi-spots‘ [69], dis-aggregated tissue from post-natal brain shown to  
re-assemble functional networks in vitro providing a human model in which patient iPSCs could be 
incorporated. However, this system remain highly variable and with limited scalability. In 2015, 
Schwartz et al. built a multi layered neural construct, containing endothelial cells and microglia, and 
used it for successful predictive toxicology using RNAseq and machine-learning technologies [70]. 
Although these 3D composite neural constructs are in the early stages, they do provide hope of the 
possibility to engineer tissue that fully mimics human brain in the future. 
4.3. Scaffolds 
Structural scaffolds to support cell growth in a 3D environment have long been a subject of 
interest for regenerative medicine, in particular for de novo generation of bone [71] and cardiac 
tissue [72]. Several companies now produce structural biomaterials with the aim of mimicking the 
mechanical and biophysical properties of human tissue to promote the 3D culture of cells into  
tissue-like structures for research and drug discovery (Table 3). 3D scaffolds for human cultures 
ideally should not use animal-derived products and they should allow cell adhesion; for technical 
applications, desirable qualities include transparency and exclude autofluorescence, to allow imaging. 
Porous scaffolds, e.g. Alvetex, Mimetix and graphene foams, are produced from animal free, inert 
materials which are cheap to produce and suitable for large scale, high-throughput applications. They 
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can be cut to size and are easy to use in the lab but often require coating in ECM proteins for cells to 
adhere to the scaffolds [71]. Electrospun scaffolds show increased neurite outgrowth [73,74]. In 
addition, graphene foams show increased conductivity compared to carbon based polymers [75], a 
property that could advance neuronal maturation in 3D cultures [76]. 
It has long been known that the stiffness of bio-scaffolds affects the neural differentiation. Ma et 
al. found that a soft graphene foam maintained stemness in NSCs whereas stiffer foams enhanced 
astrocyte differentiation [74]. As the brain parenchyma lacks rigid structural proteins, many groups 
have utilised hydrogels to create 3D models more representative of the in vivo environment (Table 3). 
Hydrogels, as the name suggests, are comprised of water and one or more ECM component e.g. 
hyaluronic acid. They can be tailored to contain any proteins desired and therefore a truly 
representative extracellular environment containing proteoglycans e.g. brevicans and tenascins could 
be achieved. Not only can the chemical properties be adjusted but also physical properties including 
viscosity and stiffness, which has been shown to encourage colony formation [77] and neurite 
extension [78]. 
Table 3. Examples of structural matrices used in 3D cultures and their application for neural cultures. 
3D Structural matrices Composition Neural culture evidence 
Alvetex Polystyrene Formation of functional glutamatergic 
synapses [124] 
Mimetix Electrospun PLLA 
microfibres 
Allows differentiation and neurite 
outgrowth of NSC (ReNeuron) 
http://www.electrospinning.co.uk/case-
studies/stem-cell-differentiation/  
Hydrogel containing 
hyaluronan and 
cellulose 
hyaluronan and 
methylcellulose in artificial 
cerebrospinal fluid 
Improved survival and integration of 
neural stem cells [125] 
Hydrogels Various ECM components 
and H2O 
PEG hydrogel for neurite outgrowth [126] 
Hydrogel stiffness affects NSC 
behaviour [127–129] 
Pyrolysed carbon Carbon rods Increased synapse formation and neurite 
outgrowth compared to 2D [76] 
Graphene foams Graphite  Biocompatable scaffold for NSC 
proliferation and differentiation [75] 
Increasing rigidity enhances 
differentiation of NSCs [74] 
Graphene hybrids Graphene oxide and 
polycaprolactone nanofibres 
Promotes oligodendrocyte lineage in 
NSCs [130] 
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4.4. Biochemical matrices and brain ECM relevant to neurodegenerative models 
Matrigel, an ECM protein mix comprising mainly Laminin111 from mouse sarcoma, has 
traditionally been used as scaffold protein in models for epithelial-mesenchymal transition (EMT), to 
investigate mechanisms of cell invasion. It has recently been used by several groups to generate 3D 
neural cultures, showing that 3D Matrigel cultures promoted survival, neurite outgrowth, synapse 
density and electrophysiological properties compared to 2D Matrigel cultures [51,79] or other 3D 
substrates [80]. However, its composition is variable and poorly defined, and there are questions 
about the inclusion of animal-derived products (substrates, serum and growth factors) in models 
designed to develop and test new human therapies. There are also questions about the suitability of 
laminin111 as a physiologically relevant structural protein in in vitro neural cultures as it is only 
present in the foetus with expression decreasing during development. Human recombinant laminin 
511 (expressed in basement membrane/blood vessel walls of adult human brain) has been suggested 
as a suitable alternative [81]. 
To avoid the issues of non-representative ECM proteins, the ideal scaffold for 3D neural models 
of degeneration would be decellularised human tissue from adult brain. As this is not available, 
characterisation of the brain ECM would permit synthesis of scaffolds to truly mimic that of the in 
vivo tissue. 
Most scaffolds are designed for generic culture rather than to specifically mimic individual 
tissue types. Brain ECM is less rigid than most other tissues comprising mainly hyaluronic acid, 
tenascins, brevicans and sulphated proteoglycans [82]. Changes in brain stiffness with age [83] and 
disease [84] would need to be considered in neurodegenerative 3D models where aging is a factor. 
Therefore a more tailored scaffold is required to mimic brain ECM, the rigidity of hydrogels are 
easily manipulated and they can be synthesized to contain any combination of ECM proteins desired 
making them the best candidate for high-throughput and drug screening assays. Hydrogel 
degradation also affects stemness and differentiation of NSCs [85]. 
4.5. Limitations 
The main limitation of current 3D models is the lack of blood and cerebral spinal fluid, to 
supply nutrients and remove waste, and the absence of the immune system. This is particularly 
important in diseases where inflammation is implicated in neurodegeneration. Advances in perfusion 
systems may go some way to resolve this. Microfluidic chips are commercially available and can, in 
part substitute for the lack of continuous nutrient provision and waste removal. As commercial 
interests in highly reproducible and robust 3D human neural cultures lie in the high-throughput drug 
screening market, microfluidic chips have been useful in this area as they have been used to assess 
the cytotoxic effects of anti-cancer agents on tumour cells [86]. However, this principle cannot 
automatically be applied to systemic therapies targeted towards CNS disorders. The lack of  
blood-brain interface and therefore the inability to assess fully drug and toxicology outcomes in these 
models may slow progress through to clinical trials. 
In conclusion, the current evidence highlights the potential advantages of 3D cultures to better 
recapitulate the in vivo environment over planar cultures. A range of 3D matrices are currently 
undergoing investigation, where further work is required to identify matrices that allow neural 
cultures to faithfully recapitulate the environment of the mature or aged adult brain. 
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5. iPSC models of AD 
5.1. Notable discoveries using 2D iPSC models in AD research 
Neurodegenerative studies using 2D iPSC-derived culture systems have for over a decade 
consistently mimicked biochemical observations in transgenic AD mice of the same genotype. 
Notably, both models displayed increased production of both Abeta40 and Abeta42 or an increased 
ratio of Abeta42/Abeta40 [87]. 2D culture models have provided evidence of how iPSCs could be 
used to test the efficacy of prospective therapies [88]. There is also proof of concept of  
high-throughput models of tau aggregation with potential for drug screening [89], which have since 
been replicated in 3D cultures [90]. 
The use of 2D models has also uncovered mechanisms of neurodegeneration, including disrupted 
calcium homeostasis, neurotoxicity, accumulation of insoluble and cleaved tau and aberrant 
phosphorylation at disease-relevant epitopes, tau-mediated mitochondrial dysfunction, oxidative  
stress [91] and interactions of tau with other proteins, such as GTPase and the cytoskeleton [92]. Many 
models exhibit physiological as well as pathological tau changes [93–95]; but they do not fully 
recapitulate the AD biochemical phenotypes as described by Choi et al. [87] where Abeta42 levels 
produced in fAD iPSCs were consistently significantly lower than those observed in AD brain. These 
2D models crucially do not form amyloid deposits or hyper-phosphorylated tau aggregate and there 
is no conclusive evidence as to the synaptic function in 2D iPSC-derived neural cultures. Only two 
studies [96,97] have so far reported increased activity of tau kinase GSK3 and resultant tau 
phosphorylation in APP mutant neurons but without changes in synaptic function, therefore 
questioning the use of this model for uncovering the mechanisms of memory loss in early AD.  
5.2. The advent of 3D iPSC models  
3D cultures have the potential to be used as more physiological human-derived high-throughput 
systems for drug screening. Thus, they have the potential to reduce the use of animal models, save 
time and costs, and reduce inter-assay variability. However, this requires that the conditions and 
characteristics of the cells (e.g. genotype, source, patient-specificity) be standardised for compound 
effect readouts. These cells should arguably also be mature enough to express key disease-relevant 
proteins and exhibit fully functional synapses.  
In 2014, Choi et al. published their seminal work, which, for the first time, showed evidence of 
extracellular amyloid deposition and tau hyperphosphorylation and aggregation into filamentous 
structures in a 3D matrix [28]. They used human neural progenitor cells (ReN cells) transfected with 
mutant APP (K670N/M617L with V717I) or APPV717I with PS1 E9 and then selected for high 
overexpression of PS1, APP and APP C-terminal fragments. Although not a physiologically relevant 
model due to greatly increased protein expression, it opened a new avenue for dementia research. 
After 3 weeks of culture, the authors reported that the cells were differentiated in neurons 
(expressing VGlut1) and glia and secreted 1000 fold higher Abeta than physiological levels. After 6 
weeks, they noted a 17 fold increased Abeta40 and Abeta42 levels in APP/PS1 culture media, with a 
5-fold increased Abeta 42:40 ratio in PS1 cells. This effect was attenuated by beta/gamma-secretase 
inhibitors, as was the presence of extracellular amyloid deposits. By 7 weeks, both 3R and 4R tau 
were present at a 1:1 ratio, which is comparable to human brain, and at 10 weeks, phosphorylation of 
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tau was increased at AT8 and PHF1 epitopes along with presence of tau aggregates in the 
somatodendritic compartment. These findings were in line with animal studies (e.g. [98]). The 
authors determined that none of the ReN cells were expressing the high AD risk ApoE e4 isoform; 
all had an e3/e3 genotype, controlling for any effects of this risk factor in the analyses. The authors 
explained that the above pathological alterations were evident in a 3D and not 2D environment due 
to the ability of 3D networks to sequester proteins in the extracellular matrix, which would otherwise 
be washed away in 2D. There is also the propensity for more complex neural connections to form 
than on planar cultures, which is key for synaptic maturation and in turn pathogenic mechanisms 
related to synaptic function and activity. Indeed, neurons exhibited extensive processes after 2–6 
weeks of differentiation and this is likely to have facilitated the increased formation of mature tau 
isoforms compared to 2D—which is integral for modelling tauopathy. 
Since Choi et al. 2014 paper, the interest in 3D models has vastly expanded to cover a variety of 
models of neurodegenerative diseases. In 2016, Raja et al. used 3D brain organoids comprising 
iPSCs-derived cells from fAD patients expressing either mutant PS1 or duplicated APP [99]. The 
fAD brain organoids consistently showed age-dependent pathological changes (including Abeta 
aggregation, tau hyperphosphorylation and endosome abnormalities) in several different mutant cell 
lines compared to controls. Treatment of organoids with beta/gamma-secretase inhibitors attenuated 
accumulation of disease-associated proteins, with the authors optimistic about the translatability and 
tractability of this 3D AD model for drug development. These cultures were subjected to biochemical 
assays at 60 and 90 days post-plating. At this time however, the centre of growing organoids began 
to show necrosis, as indicated by caspase-3 activation. In order to control for this, the authors had to 
establish a limit of 250 μm away from the surface where cells could be lysed for measurements and 
not confounded by the necrosis. The authors showed increased soluble, intracellular and aggregated 
Abeta 37–42 after 90 days and Western blotting revealed the presence of oligomeric peptides. Tau 
phosphorylation at the Ser394/Thr181 residue was observed by immunostaining and phospho-tau 
level was increased after 90 days in culture, as opposed to amyloid accumulation after 60 days. This 
may imply that phosphorylation of tau is an Abeta aggregation-induced effect. Alternatively, it might 
take longer for levels of phospho-tau, compared to Abeta aggregation, to increase past detection 
threshold. This model might support the amyloid hypothesis and evidence in AD brain [100]. FAD 
organoids also exhibited increased sizes of both small and large endosomes compared to controls, in 
line with findings in mice and both sporadic AD and fAD 2D iPSCs. 
IPSCs derived from patients with sporadic AD are now available and can be cultured in 3D. 
These may provide a crucial parallel between the mechanisms underlying two forms of AD and this 
may provide important insight into therapeutic strategies for the most common sporadic condition, 
the causes and early mechanisms of which are yet to be understood [97,101]. Lee et al. produced 3D 
neuro-spheroids using iPSCs from the blood of five advanced sporadic AD patients with no familial 
mutations [102]. These spheroids showed increased amyloidogenesis, in line with fAD models; 
interestingly, beta and gamma secretase blockers showed a lower potency for reducing amyloid load 
under 3D conditions than under 2D conditions, and only 4/5 patient-derived spheroids showed any 
efficacy of these inhibitors. Proteomic analysis revealed reductions of several proteins that the 
authors suggest might have contributed to the lower secretase potency in reducing amyloid load. 
MAP2, PAX6 and the loss of stem cell markers were used to show differentiation. While 2D neurons 
were treated after 6–8 weeks post-differentiation, 3D neurons were treated after 9 weeks, for a  
48-hour period. Abeta 40/42 was measured in conditioned media. There was reduced APP levels in 
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the 4 patient lines that showed secretase inhibitor efficacy, compared to the line where these 
inhibitors showed no effect. This finding was associated with reduced levels of clathrin heavy and 
light chains (involved in endocytosis). This study is the first 3D model of sporadic AD; however, 
non-demented control patients were not included in the experimental design, which prevents 
further insight into the amyloid production seen in sporadic AD spheroids. If Abeta levels were 
indeed measured and observed, it would have confirmed the Abeta hypothesis of sporadic AD and 
that aggregation of Abeta seen in fAD iPSC studies is not a mere result of mutations or mutant 
protein overexpression. 
Zhang et al. modelled mechanotransduction in sporadic AD using a pharmacological approach 
on differentiated neurons from iPSCs [103]. The 3D cultures displayed elevated levels of  
phospho-PAK and cytoskeletal proteins such as Debrin, and a decreased level of Cofilin, compared 
to 2D iPSCs, as observed in late stage AD brains. Treatment of 3D cultures with Abeta oligomers 
redistributed activated phospho-PAK from nuclear and cytosolic locations to submembraneous 
regions resembling the AD brain, an effect not observed in 2D iPSCs. There was a high degree of  
co-localisation of F-actin and Debrin observed in neuronal growth cones of AD cultures. As changes 
in PAK are shown in late stage AD brains, the above study provides proof-of-concept that 3D 
cultures can be used to model disease mechanisms. 
Reports of neuronal myelination observed in 3D mixed neural cultures [104] along with reduced 
variability in organoid production makes these highly variable models more amenable for drug 
screening. Experimentally, both 2D and 3D iPSC-derived cultures can be studied using a 
multidisciplinary approach as they offer a tractable in vitro environment for readouts into  
AD-relevant mechanisms, namely: electrophysiological recordings of synaptic function and plasticity 
(thought to be disrupted in early AD and lead to memory loss [105]), live imaging of calcium 
dynamics (to model early calcium changes in AD [106]) or axonal transport (which is impaired as a 
result of tau dysfunction in AD models [107,108]) and an array of molecular and biochemical 
analyses to identify the transcriptional or post-translational protein changes that are induced in AD 
and play a role in development of pathology and cell loss (such as modifications in tau protein [109]).  
6. Conclusion 
Modelling pathological processes by expressing disease-associated proteins or studying cells 
from patients with sporadic forms of disease in iPSCs is not without challenges. However, iPSCs 
offer several advantages over other cellular or tissue models: (i) most importantly, they are isogenic 
to patients enabling the study of physiologically relevant mechanistic aberrations; (ii) they allow for 
the creation of models capable of displaying the early stages of diseases and the long pre-clinical 
phases; (iii) like ESCs, they are multipotent, and thanks to the recent rapid expansion in our 
understanding of directing cell fate towards functionally-defined and region-specific neuronal 
subtypes, 3D models can now be created to mimic specific brain regions associated with disease 
aetiologies. Moreover, iPSCs do not gather the ethical concerns associated with ESCs. Other 
concerns raised over the use of iPSCs are being overcome by stem cell banks through protocol 
standardization, higher availability of patient-derived cells and development of maturation protocols 
to generate fully functional cells.  
The use of patient-specific or disease-modelled 2D iPSC cultures has provided evidence of 
disease-associated events, yet these models lack certain key features associated with disease 
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aetiology. 3D cultures incorporate a heterogeneous mix of cell types and produce a more complex 
ECM capable of retaining molecules in the intercellular space to assist in paracrine signalling. These 
factors taken together improve cell maturation and functionality to provide a model that more closely 
mimics the in vivo environment, and so far have shown promising results in term of matrices and 
environment recapitulation. 3D models are amenable to high-throughput experiments, where 
functional outputs of neuronal activity can be measured through calcium signalling and 
electrophysiology. These models are certainly applicable to the study of neurodevelopment. However, 
for neurodegeneration, the crucial factor for use as an in vitro model is the presence of fully matured, 
functioning neurons in which changes in synaptic events can be observed. This remains a challenge 
which, with all the vested interest, will soon be overcome. With the advent of ever more specific 
protocols to produce subtypes of neurons, there is a need to standardise these protocols across 
research and industry. To become viable pre-clinical disease models, 3D cultures must first be 
validated against current animal models and post mortem tissue [131]. This validation is currently 
ongoing in both academia and industry. 
Models of neurodegeneration should be ‗fit for purpose‘ and their design will ultimately depend 
on the research questions being asked of them. It is also prudent to design models that are easy to 
image and analyse, especially if investigating synaptic events. For high-throughput drug screening, 
reproducibility and automation are the key and drug exposure can be aided by the development of 
sophisticated microfluidic systems. For the 3D iPSC set up to be used routinely in drug screening, 
challenges such as high-throughput provision or standardized methods still need to be addressed but 
proof of principle that these models are well-suited have started to accumulate in the literature. 
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